Digital therapeutic maker Happify Health is partnering with neuroscience-focused pharma firm Biogen on a digital engagement and schooling platform for a number of sclerosis.
The product will embrace Happify’s group for folks residing with MS, in addition to entry to neurology suppliers like docs and nurses, psychological well being professionals, dietitians and rehabilitation professionals. Biogen will contribute academic content material and affected person care assets.
“This collaboration is considered one of some ways we’re centered on supporting sufferers by assembly them the place they’re. The mix of Biogen’s experience in neuroscience and our dedication to digital well being, together with Happify Well being’s AI and digital therapeutic capabilities, will assist drive a linked and complete expertise that permits sufferers to really feel supported all through their journey,” Jason Hawbecker, head of strategic partnerships and collaborations at Biogen, mentioned in an announcement.
“We’re excited concerning the potential of this partnership to supply general assist for the MS group.”
WHY IT MATTERS
In keeping with the National Multiple Sclerosis Society, practically a million folks have MS within the U.S. The illness could cause symptoms like numbness or tingling, weak point, issue strolling, imaginative and prescient issues and dizziness.
Happify is pitching the collaboration as a method to enhance a affected person’s care journey and hold them knowledgeable about their situation.
“It may be difficult for folks residing with MS to remain up-to-date with the newest remedies, interpret new signs or examine modifications of their well being which will or is probably not associated to MS,” Ofer Leidner, president of Happify Well being, mentioned in an announcement.
“We’re offering the MS group with an answer configured to accommodate their particular wants, in addition to alternatives to have interaction with specialists, obtain curated content material and talk about illness administration with different group members. We’re very excited to accomplice with Biogen on this chance given their management within the MS area.”
THE LARGER TREND
Happify has been on a partnership tear in current months. Earlier this month, the digital therapeutic firm announced a collaboration that’s centered on girls’s well being with insurer Anthem, which is quickly to be rebranded to Elevance Well being.
In March, Happify entered into an agreement with healthcare-services and pharmaceutical firm Zuellig Pharma to commercialize two of its prescription digital therapeutics in Asia.
The startup additionally just lately launched a digital program for folks with psoriasis in Spain, Italy and the U.Ok. as a part of a partnership with Barcelona-based pharma firm Almirall. Happify additionally closed a $73 million Series D funding round in March 2021.
Biogen is not new to the digital well being area both. In Could, it entered into a licensing agreement with prescription digital therapeutics startup MedRhythms to develop and commercialize its MR-004 product, which goals to enhance mobility for folks with a number of sclerosis.
